Document:

Amendment to Diagnostic, Collaboration and Option Agreement

 Exhibit 10.9 
 FIRST AMENDMENT TO DIAGNOSTIC COLLABORATION AND OPTION 
 AGREEMENT 
 This First Amendment to the Diagnostic Collaboration and Option Agreement (this “Amendment”) is made as of October 1, 2007, (the “Amendment
Date”) by and between CardioDX, Inc., a Delaware corporation with its principal place of business at 3183 Porter Drive, Palo Alto, California 94304 (“CardioDX”) and ARCA Discovery, Inc., a Delaware corporation having a
place of business at 1200 Seventeenth Street, Suite 620, Denver, Colorado 80202 (“ARCA”). 
 BACKGROUND

 WHEREAS, the parties entered into a Diagnostic Collaboration and Option Agreement dated as of June 23, 2006 (the
“Original Agreement”); 
 NOW THEREFORE, the parties agree to amend the Original Agreement as follows: 
 AMENDMENT 
 1.
Section 2.2(b). The following two new sentences shall be added after the last sentence of Section 2.2(b) of the Original Agreement as follows: 
 “Notwithstanding clause (i) in the previous sentence, any sublicense from ARCA to [ * ], shall be deemed to include any wholly-owned subsidiary of [ * ], including any wholly-owned
subsidiary that [ * ] acquires during the term of the sublicense between ARCA and [ * ], subject to the terms and conditions of this Agreement and the sublicense from ARCA to [ * ]. The wholly-owned subsidiaries of
[ * ] as of the date of this amendment are listed on Exhibit B hereto.” 
 2. Section 2.2(f). A new section
2.2(f) shall be added as follows: 
 “In the event a sublicense of the Genetic Marker Sublicense is properly granted hereunder by ARCA to
[ * ], and [ * ] desires to itself grant a Genetic Marker Sublicense to [ * ], ARCA shall be authorized hereunder to permit [ * ] to grant a Genetic Marker Sublicense to [ * ] directly: provided
(i) that ARCA obtains prior written approval from UC for such action; (ii) that such Sublicense shall be considered as a sublicense by ARCA for purpose of any ARCA obligation under this Agreement (including, without limitation, ARCA’s
obligations under Section 2.2(c)); and (iii) that such Sublicense complies with all other provisions of this Agreement. Such Sublicense shall also be counted as a sublicense by ARCA, for purposes of Section 2.2(a). 
 3. Exhibit A to the Original Agreement. Exhibit A to the Original Agreement shall be amended and restated in its entirety as follows:

 [ * ] 
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 1 

 3. Exhibit B. A new Exhibit B shall be hereby added to the Original Agreement and read as
follows: 
 “EXHIBIT B 
 [ * ] 
 4. No
Other Amendments. Except as otherwise amended by this Amendment, all other terms and conditions in the Original Agreement will remain in full force and effect. 
 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their respective duly authorized officers or representatives as of the Amendment Date. 
  

									
	CARDIODX, INC.	 		 	ARCA DISCOVERY, INC.
					
	By:	 	/s/ David Levinson	 		 	By:	 	/s/ Christopher D. Ozeroff
	Name:	 	David Levinson	 		 	Name:	 	Christopher D. Ozeroff
	Title:	 	President & CEO	 		 	Title:	 	EVP Bus. Dev. and General Counsel
	Date:	 	October 29, 2007	 		 	Date:	 	October 23, 2007

  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 2Manufacturing Agreement, dated September 11, 2006

 Exhibit 10.10 
 PATHEON PROPOSAL :ARC-FYM1-0800-0406-R5 
  

					
			
	 1.      Parties:
	  	Patheon Inc. (“Patheon”)	  	ARCA Discovery, Inc. (“Client”)
		  	7070 Mississauga Road, Suite 350	  	1400 – 16th Street, Suite 220
		  	Mississauga, Ontario	  	Denver, Colorado 80202
		  	Canada	  	
		
	 2.      Product:
	  	 •       Bucindolol HCl Tablets (six strengths)
(“Product”)

		
	 3.      Indication: 
	  	 •       Heart Failure

		
	 4.      Contract: 
	  	This Proposal (including the Project Scope, Budget Summary, Standard Terms and Conditions for Pharmaceutical Development Services (“Terms and Conditions”) when accepted by
Client shall become a contract binding on the parties (“Contract”).
		
	 5.      Description of Services: 
	  	See Project Scope (Part A).
		
	 6.      Payment and Currency: 
	  	See Budget Summary (Part B).
		
	 7.      Legal Terms: 
	  	See Terms and Conditions (Part C).
		
	 8.      Effective Date: 
	  	                    , 200
		
	 9.      Term: 
	  	From the Effective Date until completion by Patheon of the pharmaceutical development services (“Services”).
		
	 10.    Date of Confidentiality Agreement:
	  	March 8, 2006
		
	 11.    Date of PatheonPartnerTM External User Account / Access Form 
	  	                    , 200 [If applicable]
		
	 12.    Date: 
	  	                    , 200

  

									
	Patheon Inc.	 		 	ARCA Discovery, Inc.
					
	By:	 	/s/ Nicholas Dowd	 		 	By:	 	Christopher Ozeroff
	Name:	 	Nicholas Dowd	 		 	Name:	 	Christopher Ozeroff
	Title:	 	V.P. & Controller	 		 	Title:	 	EVP Business Development & GC

 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

 Table of Contents 
  

					
	Part A: PROJECT SPECIFICS AND DETAILS	  	
			
	 1.
	  	PROJECT SCOPE	  	5
			
	 2.
	  	PROJECT INITIATION	  	6
			
	 3.
	  	ENVIRONMENTAL, HEALTH AND SAFETY	  	6
			
	 4.
	  	ANALYTICAL DEVELOPMENT	  	6
			
		  	 4.1.  Cleaning Residuals Assay (Method Evaluation and Validation)
	  	6
			
		  	 4.2.  Drug Product Potency and Related Substances Assay (Method Inter Lab Qualification)
	  	6
			
		  	 4.3.  Drug Product Dissolution Assay – Profile by HPLC (Method Development)
	  	6
			
		  	 4.4.  Drug Product Dissolution Assay – Profile by HPLC (Method Validation – six strengths)
	  	6
			
	 5.
	  	FEASIBILITY MANUFACTURING – 3.125, 6.25 AND 12.5 MG	  	7
			
	 6.
	  	FEASIBILITY MANUFACTURING – 25, 50 AND 100 MG	  	8
			
	 7.
	  	CTM / REGISTRATION MANUFACTURING – 3.125, 6.25 AND 12.5 MG	  	9
			
	 8.
	  	CTM / REGISTRATION MANUFACTURING – 25, 50 AND 100 MG	  	10
			
	 9.
	  	STABILITY – CTM / REGISTRATION BATCHES	  	12
			
	 10.
	  	VALIDATION	  	14
			
	 11.
	  	STABILITY – VALIDATION	  	15
			
	 12.
	  	PROJECT SUPPORT	  	17
			
	 13.
	  	HIGH LEVEL TIMELINE	  	17
			
	 14.
	  	GENERAL INFORMATION	  	18
		
	 Standard Assumption:
	  	18

  

 ARCA Discovery, Inc. 
 Bucindolol HCl Tablets (six strengths) - Technology Transfer 
 Page 2 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

 PART B: BUDGET SUMMARY 
 PART C: LEGAL TERMS AND CONDITIONS 
  

 ARCA Discovery, Inc. 
 Bucindolol HCl Tablets (six strengths) - Technology Transfer 
 Page 3 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

 PART A: 
 Bucindolol HCl Tablets (six strengths) 
 Technology Transfer 
 For 
 ARCA Discovery, Inc.

 Proposal No.: ARC-FYM1-0800-0406-R5 
 Dated: 21-September-2006 
  

 ARCA Discovery, Inc. 
 Bucindolol HCl Tablets (six strengths) - Technology Transfer 
 Page 4 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

 The proposal outlines the Services that Patheon is proposing to perform for the Client relating to the Product. The
initial sections describe the Services to be performed by Patheon that address Client’s specific project requirements. The section below entitled General Information provides additional background information on pharmaceutical
development services by Patheon. The check boxes under the General Information section will indicate whether or not a particular item is applicable to this specific project. 
  

	1.	Project Scope 

 For general information on the pharmaceutical
development services provided by Patheon please refer to the section below entitled “General Information”. 
 Patheon will perform the following
activities to support the Technology Transfer of Bucindolol HCl Tablets (six strengths): 
  

	 	•	 	 Project Initiation 

  

	 	•	 	 Environmental, Health and Safety 

  

	 	•	 	 Analytical Services 

  

	 	•	 	 Manufacturing 

  

	 	•	 	 Stability 

  

	 	•	 	 Validation 

 This proposal has been adjusted to
reflect a campaign of three common granulation batches, each compressed into 2 or 3 strengths for a total of 5 or 7 lots required for registration (per campaign price). 
 In order to support the technology transfer the following capital expenditures need to be made at the sole expense of the Client: 
  

	 	•	 	 Blister tooling ~$30,000 per set x 1 set = $30,000 

  

	 	•	 	 Compressing tooling ~$7,000 per round set 

                         ~$14,000 per shaped set 
 All estimated costs are quoted in USD. A 15% handling fee will not be applied to tooling and change parts (only applicable to project consumables. 
 Prior to expanding the capital expenditures, the Client shall pre-pay Patheon for all costs of the capital expenditures. Therefore, Patheon shall order the necessary equipment and provide invoices to the Client for
the costs of the equipment. 
  

 ARCA Discovery, Inc. 
 Bucindolol HCl Tablets (six strengths) - Technology Transfer 
 Page 5 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

 In the budget summary, a rebate of $100,000 USD over first 20 commercial batches is applied at the validation stage.
A 10% discount is applied to each milestone. 
  

	2.	Project Initiation 

 Project Initiation Fee covers a series of
activities at the start of a project that are performed by cross functional team members. 
  

	3.	Environmental, Health and Safety 

 Active Pharmaceutical
Ingredient(s): 
  

	 	•	 	 Bucindolol HCl 

  

	 	•	 	 Patheon’s preliminary categorization = Category 2 

 Prior to the commencement of analytical method development, formulation development and manufacturing activities, a thorough review by Patheon of the Environmental, Health and Safety (EH&S) requirements for Drug Substance will be
completed. The Budget Summary for this Project Scope assumes that the EH&S review will determine that Drug Substance can be safely handled at Patheon. A summary report of the evaluation will be provided to the Client. 
  

	4.	Analytical Development 

 Patheon will perform method evaluation,
validation and inter-laboratory qualification for the Client. 
 A protocol and report will be generated for each method to support the analytical work.

 Analytical Methods 
  

	4.1.	Cleaning Residuals Assay (Method Evaluation and Validation) 

  

	4.2.	Drug Product Potency and Related Substances Assay (Method Inter Lab Qualification) 

  

	4.3.	Drug Product Dissolution Assay – Profile by HPLC (Method Development) 

  

	4.4.	Drug Product Dissolution Assay – Profile by HPLC (Method Validation – six strengths) 

  

 ARCA Discovery, Inc. 
 Bucindolol HCl Tablets (six strengths) - Technology Transfer 
 Page 6 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

	5.	Feasibility Manufacturing – [ * ], [ * ] and [ * ] mg 

 Patheon will manufacture: 
  

	 	•	 	 Bucindolol HCl Tablets ([ * ], [ * ] and [ * ] mg strengths) 

  

	 	•	 	 One (1) batch compressed into three (3) tablet strengths 

  

	 	•	 	 Approximately [ * ] kilograms 

  

	 	•	 	 Common blend approach for three (3) strengths 

  

	 	•	 	 Excipients released as per USP/NF 

  

	 	•	 	 Batch record 

  

	 	•	 	 Bulk packaged 

  

	 	•	 	 cGMP conditions 

  

	 	•	 	 No QA review 

 Feasibility Manufacturing Process
Train: 
  

	 	•	 	 Blender 

  

	 	•	 	 Tablet Press 

  

	 	•	 	 Tablet Coater 

 The following in-process and finished
product testing is based upon one set of analysis for each of the described tests. If additional sample testing is required, these will be considered as additional activities for which a separate costing will be provided to the Client. 

Testing (one set of analysis): 
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 ARCA Discovery, Inc. 
 Bucindolol HCl Tablets (six strengths) - Technology Transfer 
 Page 7 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

			
	 In-Process Testing:
  
 •        Blend Homogeneity
 (One blend, 10 samples)
  
 •        Flow Properties
  
 •        Bulk
and Tap Densities
 (Including one sieve analysis)
  
 •        Moisture (LOD or KF)
  
 •        Physical Parameters (ie. appearance, weight, weight variation, hardness,
thickness, disintegration, friability for beginning, middle and end run)
	  	 Finished Product Testing per strength:
  
 •        Content Uniformity (as per USP)
  
 •        Potency and Related Substances
  
 •        Dissolution (profile)
  
 •        Moisture (LOD or KF)

  

	6.	Feasibility Manufacturing – [ * ], [ * ] and [ * ] mg 

 Patheon will manufacture: 
  

	 	•	 	 Bucindolol HCl Tablets ([ * ], [ * ] and [ * ] strengths) 

  

	 	•	 	 One (1) batch compressed into three (3) tablet strengths 

  

	 	•	 	 Approximately [ * ] kilograms 

  

	 	•	 	 Common blend approach for three (3) strengths 

  

	 	•	 	 Excipients released as per USP/NF 

  

	 	•	 	 Batch record 

  

	 	•	 	 Bulk packaged 

  

	 	•	 	 cGMP conditions 

  

	 	•	 	 No QA review 

  

	 	•	 	 Manufacturing report 

 Feasibility Manufacturing
Process Train: 
  

	 	•	 	 Blender 

  

	 	•	 	 Tablet Press 

  

	 	•	 	 Tablet Coater 

 The following in-process and finished
product testing is based upon one set of analysis for each of the described tests. If additional sample testing is required, these will be considered as additional activities for which a separate costing will be provided to the Client. 

 

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 ARCA Discovery, Inc. 
 Bucindolol HCl Tablets (six strengths) - Technology Transfer 
 Page 8 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

 Testing (one set of analysis): 
  

			
	 In-Process Testing:
  
 •        Blend Homogeneity
 (One blend, 10 samples)
  
 •        Flow Properties
  
 •        Bulk
and Tap Densities
 (Including one sieve analysis)
  
 •        Moisture (LOD or KF)
  
 •        Physical Parameters (ie. appearance, weight, weight variation, hardness,
thickness, disintegration, friability for beginning, middle and end run)
	  	 Finished Product Testing per strength:
  
 •        Content Uniformity (as per USP)
  
 •        Potency and Related Substances
  
 •        Dissolution (profile)
  
 •        Moisture (LOD or KF)

  

	7.	CTM / Registration Manufacturing – [ * ], [ * ] and [ * ] mg 

 Patheon will manufacture: 
  

	 	•	 	 Bucindolol HCl Tablets ([ * ], [ * ] and [ * ] mg strengths) 

  

	 	•	 	 One (1) batch compressed into three (3) strengths 

  

	 	•	 	 Approximately [ * ] kilograms 

  

	 	•	 	 Common blend approach for three (3) strengths, compressed as follows: 

  

	 	•	 	 [ * ] mg – 3 batches 

  

	 	•	 	 [ * ] mg – 2 batches 

  

	 	•	 	 [ * ] mg – 2 batches 

  

	 	•	 	 Excipients release as per USP/NF 

  

	 	•	 	 Batch record 

  

	 	•	 	 Packaged into PVC/PVDC blister, HDPE bottles (two counts – to be determined) 

  

	 	•	 	 cGMP conditions 

  

	 	•	 	 QA review 

 CTM / Registration Manufacturing Process
Train: 
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 ARCA Discovery, Inc. 
 Bucindolol HCl Tablets (six strengths) - Technology Transfer 
 Page 9 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

	 	•	 	 Blender 

  

	 	•	 	 Tablet Press 

  

	 	•	 	 Tablet Coater 

 The following in-process and finished
product testing is based upon one set of analysis for each of the described tests. If additional sample testing is required, these will be considered as additional activities for which a separate costing will be provided to the Client. 

Testing (one set of analysis): 
  

			
	 In-Process Testing:
  
 •        Blend Homogeneity
 (One blend, 10 samples)
  
 •        Flow Properties
  
 •        Bulk
and Tap Densities
 (Including one sieve analysis)
  
 •        Moisture (LOD or KF)
  
 •         Physical Parameters (ie. appearance, weight, weight variation,
hardness, thickness, disintegration, friability for beginning, middle and end run)
	  	 Finished Product Testing per lot:
  
 •        Content Uniformity (as per USP)
  
 •        Potency and Related Substances
  
 •        Dissolution (profile)
  
 •        Moisture (LOD or KF)

  

	8.	CTM / Registration Manufacturing – [ * ], [ * ] and [ * ] mg 

 Patheon will manufacture: 
  

	 	•	 	 Bucindolol HCl Tablets ([ * ], [ * ] and [ * ] mg strengths) 

  

	 	•	 	 One (1) batch compressed into three (3) strengths 

  

	 	•	 	 Approximately [ * ] kilograms 

  

	 	•	 	 Common blend approach for three (3) strengths, compressed as follows: 

  

	 	•	 	 [ * ] mg – 3 batches 

  

	 	•	 	 [ * ] mg – 2 batches 

  

	 	•	 	 [ * ] mg – 2 batches 

  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 ARCA Discovery, Inc. 
 Bucindolol HCl Tablets (six strengths) - Technology Transfer 
 Page 10 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

	 	•	 	 Excipients release as per USP/NF 

  

	 	•	 	 Batch record 

  

	 	•	 	 Packaged into PVC/PVDC blister, HDPE bottles (two counts – to be determined) 

  

	 	•	 	 cGMP conditions 

  

	 	•	 	 QA review 

  

	 	•	 	 Manufacturing report 

 CTM / Registration
Manufacturing Process Train: 
  

	 	•	 	 Blender 

  

	 	•	 	 Tablet Press 

  

	 	•	 	 Tablet Coater 

 The following in-process and finished
product testing is based upon one set of analysis for each of the described tests. If additional sample testing is required, these will be considered as additional activities for which a separate costing will be provided to the Client. 

Testing (one set of analysis): 
  

			
	 In-Process Testing:
  
 •        Blend Homogeneity
 (One blend, 10 samples)
  
 •        Flow Properties
  
 •        Bulk
and Tap Densities
 (Including one sieve analysis)
  
 •        Moisture (LOD or KF)
  
 •         Physical Parameters (ie. appearance, weight, weight variation,
hardness, thickness, disintegration, friability for beginning, middle and end run)
	  	 Finished Product Testing per lot:
  
 •        Content Uniformity (as per USP)
  
 •        Potency and Related Substances
  
 •        Dissolution (profile)
  
 •        Moisture (LOD or KF)

  

 ARCA Discovery, Inc. 
 Bucindolol HCl Tablets (six strengths) - Technology Transfer 
 Page 11 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

	9.	Stability – CTM / Registration Batches 

 The proposed
stability program is based on three (3) registration batches per strength (six strengths) packaged into three (3) configurations. Alternative approaches can be discussed with the Client. 
 Bracket/Matrix Proposal for Bucindolol HCl Tablets 
  

																																																									
	 Batch
	  	1	  	2	  	3
	 Strength (mg)
	  	[ * ]
(Note 1)	  	[ * ]
(Note 1)	  	[ * ]
(Note 1)	  	[ * ]
(Note 1)	  	[ * ]
(Note 1)	  	[ * ]
(Note 1)	  	[ * ]
(Note 1)	  	[ * ]
(Note 1)	  	[ * ]
(Note 1)
	 Container
 (Note 2)
	  	C1	  	C2	  	C3	  	C1	  	C2	  	C3	  	C1	  	C2	  	C3	  	C1	  	C2	  	C3	  	C1	  	C2	  	C3	  	C1	  	C2	  	C3	  	C1	  	C2	  	C3	  	C1	  	C2	  	C3	  	C1	  	C2	  	C3
	Schedule	  	T1	  	T2	  	T3	  		  		  		  	T3	  	T1	  	T2	  	T2	  	T3	  	T1	  		  		  		  	T1	  	T2	  	T3	  	T3	  	T1	  	T2	  		  		  		  	T2	  	T3	  	T1
	 Time
 Point
 (Months)
	  	0	  	X	  	X	  	X	  		  		  		  	X	  	X	  	X	  	X	  	X	  	X	  		  		  		  	X	  	X	  	X	  	X	  	X	  	X	  		  		  		  	X	  	X	  	X
	  	3	  	X	  	X	  		  		  		  		  		  	X	  	X	  	X	  		  	X	  		  		  		  	X	  	X	  		  		  	X	  	X	  		  		  		  	X	  		  	X
	  	6	  		  	X	  	X	  		  		  		  	X	  		  	X	  	X	  	X	  		  		  		  		  		  	X	  	X	  	X	  		  	X	  		  		  		  	X	  	X	  	
		  	9	  	X	  		  	X	  		  		  		  	X	  	X	  		  		  	X	  	X	  		  		  		  	X	  		  	X	  	X	  	X	  		  		  		  		  		  	X	  	X
		  	12	  	X	  	X	  	X	  		  		  		  	X	  	X	  	X	  	X	  	X	  	X	  		  		  		  	X	  	X	  	X	  	X	  	X	  	X	  		  		  		  	X	  	X	  	X
		  	18	  	X	  		  		  		  		  		  		  	X	  		  		  		  	X	  		  		  		  	X	  		  		  		  	X	  		  		  		  		  		  		  	X
		  	24	  		  	X	  	X	  		  		  		  	X	  		  	X	  	X	  	X	  		  		  		  		  		  	X	  	X	  	X	  		  	X	  		  		  		  	X	  	X	  	
		  	36	  	X	  	X	  	X	  		  		  		  	X	  	X	  	X	  	X	  	X	  	X	  		  		  		  	X	  	X	  	X	  	X	  	X	  	X	  		  		  		  	X	  	X	  	X

  

	*	This design is recommending a combined bracketed and matrixed approach. A full study program would require 54 lots with 8 pull points for a total of 432 analytical samples. This
design reduces it to 36 lots because of the bracket design. With 8 pull points, this would give a total of 288 analytical samples which is equivalent to a reduction of about 33%. 

 The matrix design reduces the number of pull points to 6 which leads to a total of 216 analytical samples - equivalent to a reduction of about 50%. It is clear that the
majority of this reduction arises from the bracketing. 
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 ARCA Discovery, Inc. 
 Bucindolol HCl Tablets (six strengths) - Technology Transfer 
 Page 12 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

 One reason for this is that it is mandatory that every sample be tested at T=0 and T=36 months (end of shelf life).
In addition it is assumed that an NDA will be filed at 12 months and so every sample must be tested at this time point. If a different filing date is intended, the matrix can be modified accordingly. 
 In order to justify any such reduced study design, it is important that the client has stability data already available on this product (or one that is very similar and
the data indicate that this product undergoes little or no change and that there is little or no variance in the analytical data). 
 It is also recommended
that the design be discussed with appropriate Regulatory Agencies prior to commencement to ensure that they will accept it. 
  

 ARCA Discovery, Inc. 
 Bucindolol HCl Tablets (six strengths) - Technology Transfer 
 Page 13 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

 Testing per sample: 
  

	 	•	 	 Potency and Related substances 

  

	 	•	 	 Dissolution (profile) 

  

	 	•	 	 Physical testing including appearance 

  

	10.	Validation 

 Patheon will complete: 
  

	 	•	 	 Validation activities on 14 validation batches 

  

	 	•	 	 [ * ] mg – 3 batches 

  

	 	•	 	 [ * ] mg – 2 batches 

  

	 	•	 	 [ * ] mg – 2 batches 

  

	 	•	 	 [ * ] mg – 2 batches 

  

	 	•	 	 [ * ] mg – 2 batches 

  

	 	•	 	 [ * ] mg – 3 batches 

  

	 	•	 	 Protocols prepared for the Master Validation plan, processing validation, packaging validation, equipment qualification/validation and cleaning validation

 The scope and degree of the validation will be discussed and approved by the Client before proceeding. Since final validation approach
has not yet been defined, a typical costing has been presented for review. A final budget cost will be proposed to the Client once a validation protocol has been agreed upon. 
 Validation costs listed in this proposal are for validation of 14 commercial batches. Manufacturing costs for the validation batches are additional and will be based on commercial rates. 
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 ARCA Discovery, Inc. 
 Bucindolol HCl Tablets (six strengths) - Technology Transfer 
 Page 14 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

	11.	Stability – Validation 

 The proposed stability program is
based on three (3) registration batches per strength (six strengths) packaged into three (3) configurations. Alternative approaches can be discussed with the Client. 
 Bracket/Matrix Proposal for Bucindolol HCl Tablets 
  

																																																									
	 Batch
	  	1	  	2	  	3
	 Strength (mg)
	  	[ * ]
(Note 1)	  	[ * ]
(Note 1)	  	[ * ]
(Note 1)	  	[ * ]
(Note 1)	  	[ * ]
(Note 1)	  	[ * ]
(Note 1)	  	[ * ]
(Note 1)	  	[ * ]
(Note 1)	  	[ * ]
(Note 1)
	 Container
 (Note 2)
	  	C1	  	C2	  	C3	  	C1	  	C2	  	C3	  	C1	  	C2	  	C3	  	C1	  	C2	  	C3	  	C1	  	C2	  	C3	  	C1	  	C2	  	C3	  	C1	  	C2	  	C3	  	C1	  	C2	  	C3	  	C1	  	C2	  	C3
	Schedule	  	T1	  	T2	  	T3	  		  		  		  	T3	  	T1	  	T2	  	T2	  	T3	  	T1	  		  		  		  	T1	  	T2	  	T3	  	T3	  	T1	  	T2	  		  		  		  	T2	  	T3	  	T1
	 Time Point
 (Months)
	  	0	  	X	  	X	  	X	  		  		  		  	X	  	X	  	X	  	X	  	X	  	X	  		  		  		  	X	  	X	  	X	  	X	  	X	  	X	  		  		  		  	X	  	X	  	X
	  	3	  	X	  	X	  		  		  		  		  		  	X	  	X	  	X	  		  	X	  		  		  		  	X	  	X	  		  		  	X	  	X	  		  		  		  	X	  		  	X
	  	6	  		  	X	  	X	  		  		  		  	X	  		  	X	  	X	  	X	  		  		  		  		  		  	X	  	X	  	X	  		  	X	  		  		  		  	X	  	X	  	
		  	9	  	X	  		  	X	  		  		  		  	X	  	X	  		  		  	X	  	X	  		  		  		  	X	  		  	X	  	X	  	X	  		  		  		  		  		  	X	  	X
		  	12	  	X	  	X	  	X	  		  		  		  	X	  	X	  	X	  	X	  	X	  	X	  		  		  		  	X	  	X	  	X	  	X	  	X	  	X	  		  		  		  	X	  	X	  	X
		  	18	  	X	  		  		  		  		  		  		  	X	  		  		  		  	X	  		  		  		  	X	  		  		  		  	X	  		  		  		  		  		  		  	X
		  	24	  		  	X	  	X	  		  		  		  	X	  		  	X	  	X	  	X	  		  		  		  		  		  	X	  	X	  	X	  		  	X	  		  		  		  	X	  	X	  	
		  	36	  	X	  	X	  	X	  		  		  		  	X	  	X	  	X	  	X	  	X	  	X	  		  		  		  	X	  	X	  	X	  	X	  	X	  	X	  		  		  		  	X	  	X	  	X

  

	*	This design is recommending a combined bracketed and matrixed approach. A full study program would require 54 lots with 8 pull points for a total of 432 analytical samples. This
design reduces it to 36 lots because of the bracket design. With 8 pull points, this would give a total of 288 analytical samples which is equivalent to a reduction of about 33%. 

 The matrix design reduces the number of pull points to 6 which leads to a total of 216 analytical samples - equivalent to a reduction of about 50%. It is clear that the
majority of this reduction arises from the bracketing. 
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 ARCA Discovery, Inc. 
 Bucindolol HCl Tablets (six strengths) - Technology Transfer 
 Page 15 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

 One reason for this is that it is mandatory that every sample be tested at T=0 and T=36 months (end of shelf life).
In addition it is assumed that an NDA will be filed at 12 months and so every sample must be tested at this time point. If a different filing date is intended, the matrix can be modified accordingly. 
 In order to justify any such reduced study design, it is important that the client has stability data already available on this product (or one that is very similar and
the data indicate that this product undergoes little or no change and that there is little or no variance in the analytical data). 
 It is also recommended
that the design be discussed with appropriate Regulatory Agencies prior to commencement to ensure that they will accept it. 
  

 ARCA Discovery, Inc. 
 Bucindolol HCl Tablets (six strengths) - Technology Transfer 
 Page 16 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

 Testing per sample: 
  

	 	•	 	 Potency and Related substances 

  

	 	•	 	 Dissolution (profile) 

  

	 	•	 	 Physical testing and appearance 

  

	12.	Project Support 

 Patheon will provide project management support to
monitor the progress of the project against established timelines and will provide the Client with frequent updates. The project manager will coordinate regular biweekly teleconference meetings and quarterly face-to-face meetings. The fee for
project management is incorporated in the breakdown cost for each activity in the Budget Summary. 
  

	13.	High Level Timeline 

 The attached High Level Timeline is presented
at this stage as a projected estimate of the duration and achievable milestones, based upon Patheon’s experience and history. The High Level Timeline should not be taken as part of an agreed legal deliverable of this proposal. 
 Once the project has been awarded to Patheon and the relevant legal documentation is in place, a revised Timeline detailing set milestones and duration of deliverables
will be agreed upon between Patheon and the Client. The revised Timeline would likely have a similar duration and would be based upon resources and the availability of manufacturing time at the initiation of the project. 
  

 ARCA Discovery, Inc. 
 Bucindolol HCl Tablets (six strengths) - Technology Transfer 
 Page 17 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

	14.	General Information 

 This section provides additional background
information on the pharmaceutical development services performed by Patheon, The check boxes below indicate whether or not a particular item is applicable to the project described above. 
 Standard Assumption: 
  

	 	1.	The approach used would be outlined in a more detailed protocol prepared by Patheon and on request approved by the Client. Further studies may be required in the later development
stages of the project. Where required these would be discussed and agreed separately with the Client. 

  

	 	2.	It is assumed that the drug substance and/or formulation does not absorb/adsorb to any metal, glass or other components used during the processing and analytical testing of the
batch. The fees for any investigational work associated with drug substance and/or formulation interacting with components are not included within this proposal. 

  

	 	3.	The identification of unknown impurities detected during the study is not included as part of this proposal. 

 A) Project Initiation 
  

							
	x	  	Applicable	  	 ̈	  	Not Applicable

 The Project Initiation Fee covers a series of activities at the start
of a project. These activities include (but are not limited to) scientific review of Client documentation, literature research and review, procurement of project specific equipment and
tooling, analytical method research and attendance by cross functional team members for initial Client “kick-off “ meetings.
 B) Environmental, Health & Safety 
  

							
	x	  	Applicable	  	 ̈	  	Not Applicable

 If it is determined by Patheon’s Environmental Health and Safety personnel that any of the active ingredients
are a Category III or Category IV compound (an occupational exposure level) then an air sampling method will be required at Client’s expense prior to commercialization. Patheon reserves the right, in its sole and absolute discretion, to conduct
an air sampling method on Category I and II compounds, at such price and upon such terms as may be mutually agreed to between the parties prior to commercialization. 
 Prior to commercialization, Patheon will evaluate the Product and the proposed launch volume and, at the Client’s request, select the appropriate Patheon facility for commercialization. The Patheon facility used
for performance of the Services will not necessarily be the facility available for commercialization. 
 Patheon will not receive any active pharmaceutical
ingredients (API) from the Client until a MSDS has been received, Patheon has completed the categorization of the API and that the Client has completed and returned the EH&S Survey to Patheon. 
  

 ARCA Discovery, Inc. 
 Bucindolol HCl Tablets (six strengths) - Technology Transfer 
 Page 18 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

 C) Analytical Development 
 Analytical Protocols and Reports 
  

							
	x	  	Applicable	  	 ̈	  	Not Applicable

 Analytical protocols will be drafted by Patheon for validation activities only and submitted to the Client for
approval prior to execution with the exception of the Cleaning Residuals Assay, which will be approved internally by Patheon. No protocols will be issued for method development activities. Upon completion of the development activities, a summary of
the data will be provided to the Client. The analytical methods have been based upon HPLC unless otherwise stated. 
 An analytical report will be provided
to the Client once the method validation is complete. If method validation is not specified in the title of an analytical method under this Project Scope, then the validation of such analytical method is not included in this Project Scope and the
additional method validation costs will be quoted separately by Patheon. 
 API Receipt and Release 
  

							
	x	  	Applicable	  	 ̈	  	Not Applicable

 Patheon will receive and release the active pharmaceutical ingredients (API) for Clinical Trial Material (CTM)
manufacture based on the following: (i) Identification testing; and (ii) the accompanying Certificate of Analysis (COA) from the API Vendor (Client qualified) and COA from the Client. 
 Reference Standards for Drug Substances and Related Substances 
  

							
	x	  	Applicable	  	 ̈	  	Not Applicable

 The Client shall provide Patheon with accurate, appropriate, sufficient and the most current applicable reference
standards (such as USP, NF, BP, EP, and JP for the drug substances and related substances to complete the scope of work outlined herein. 
 Method
Development 
  

							
	 ̈	  	Applicable	  	x	  	Not Applicable

 Patheon will develop the test method required to support the Project. The method development will cover the sample
preparation procedures, HPLC conditions, calibration procedures, specificity, detection limit (if applicable), quantitation limit (if applicable), accuracy and repeatability. 
 Forced Degradation Study 
  

							
	 ̈	  	Applicable	  	x	  	Not Applicable

 In order to assess whether the drug substance or drug product potency assay is suitable for use as
stability–indicating assay, a series of experiments will be performed to study degradation. The drug substance or drug product will be treated with acidic, basic, oxidative, light and thermal conditions, the stressed samples will
be analyzed by the potency method using DAD and ensure that the active peak is pure from peak purity assessment. If the peak purity fails, the method needs to be redeveloped for stability-indicating, and a change of scope will be issued.

  

 ARCA Discovery, Inc. 
 Bucindolol HCl Tablets (six strengths) - Technology Transfer 
 Page 19 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

 Drug Product Dissolution Assay by HPLC (Method Development) 
  

							
	 ̈	  	Applicable	  	x	  	Not Applicable

 Patheon will develop the assay required for testing dissolution of the drug product. The development will
challenge the following parameters: 
  

			
	 •        Sink condition
  
 •        Selection of medium, apparatrus speed
  
 •        Optimization of medium conc. & pH
  
 •        System
suitability
	  	 •        Specificity
  
 •        Accuracy
  
 •        Repeatability

 Interlab Qualification 
  

							
	x	  	Applicable	  	 ̈	  	Not Applicable

 Inter-Laboratory Qualification involves the comparison of two different series of laboratory analyses for the same
lot of material/product. This verifies that both laboratories (i.e., the originating and receiving laboratories) are following the same procedure accurately and producing results that are precise and equivalent. The Client needs to provide to
Patheon the method validation report. The following parameters will be performed at both Patheon and the originating laboratory: 
  

			
	 •        System Suitability
  
 •        Stability of Standard and Sample Solution
  
 •        Repeatability
	  	 •        Quantitation Limit (if applicable)
  
 •        Detection Limit (if applicable)

 Method Transfer 
  

							
	 ̈	  	Applicable	  	x	  	Not Applicable

 Method Transfer is an on site validation process in the receiving laboratory, which verifies that method performs
in the receiving laboratory in an equivalent manner to the originating laboratory. The Client needs to provide to Patheon the method validation report. The following parameters will be performed at Patheon as the receiving laboratory: 
  

			
	 •        System Suitability
  
 •        Linearity
  
 •        Stability of Standard and Sample Solutions
	  	 •        Repeatability
  
 •        Quantitation Limit (if applicable)
  
 •        Detection Limit (if applicable)

 Method Evaluation 
  

							
	x	  	Applicable	  	 ̈	  	Not Applicable

 Patheon will evaluate the test method(s) required to support the Project. Method evaluation will cover the
sample preparation procedures, HPLC conditions, calibration procedures, specificity, accuracy, repeatability and detection/quantitation limits (if appropriate). If the method(s) is/are deemed unsuitable, new method(s) will be developed and
billed as a change of scope 
  

 ARCA Discovery, Inc. 
 Bucindolol HCl Tablets (six strengths) - Technology Transfer 
 Page 20 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

 Method Validation Phase Levels 
 Patheon will validate the test method required to support the Project. The validation will challenge the following parameters based on the Project Clinical Phase Level: 
 Phase I 
  

							
	 ̈	  	Applicable	  	x	  	Not Applicable

  

			
	 •        System Suitability
  
 •        Linearity
  
 •        Specificity
  
 •        Range
  
 •        Accuracy
	  	 •        Repeatability
  
 •        Solution Stability
  
 •        Quantitation Limit (if applicable)
  
 •        Detection Limit (if applicable)

 Phase II 
  

							
	 ̈	  	Applicable	  	x	  	Not Applicable

  

			
	 •        System Suitability
  
 •        Linearity
  
 •        Specificity
  
 •        Range
  
 •        Accuracy
	  	 •        Intermediate Precision
  
 •        Repeatability
  
 •        Solution Stability
  
 •        Quantitation Limit (if applicable)
  
 •        Detection Limit (if applicable)

 Phase III 
  

							
	x	  	Applicable	  	 ̈	  	Not Applicable

  

			
	 •        System Suitability
  
 •        Linearity
  
 •        Specificity
  
 •        Range
  
 •        Accuracy
  
 •        Intermediate Precision
	  	 •        Repeatability
  
 •        Solution Stability
  
 •        Robustness
  
 •        Quantitation Limit (if applicable)
  
 •        Detection Limit (if applicable)

 D) Microbiology 
  

							
	 ̈	  	Applicable	  	x	  	Not Applicable

 The cost allocated to this Service in the Budget Summary of Part B is the per sample price and will vary depending
on the number of samples required for method validation. If a worst case scenario approach were taken, the cost would be based upon testing MLT and PET (if applicable) at two dilutions and/or the usage of the largest volume of diluent(s) based on
specification. Testing will be done in compliance with the applicable Pharmacopeia (ie. USP/NF, EP, JP etc.). Client will be billed based on the actual number of samples required in order to successfully validate the Product. 
  

 ARCA Discovery, Inc. 
 Bucindolol HCl Tablets (six strengths) - Technology Transfer 
 Page 21 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

 E) Stability 
  

							
	x	  	Applicable	  	 ̈	  	Not Applicable

 The analytical data used for the release of each lot manufactured at Patheon will be considered as initial (T=0)
data if the stability study commences not more than 1 month after release testing. 
 Cost efficiencies for analytical testing have been built into the
stability program based upon the number of samples pulled in a given month. The cost for this stability program assumes that all lots will be placed on stability at the same time. If these lots are not placed on stability at the same time, the cost
will be adjusted accordingly through a Change of Scope Agreement. 
 F) Formulation Development, Manufacturing, Protocols and Reports 
  

							
	 ̈	  	Applicable	  	x	  	Not Applicable

 Formulation Development 
 The approach used in formulation development would be outlined in a detailed protocol prepared by Patheon and approved by the Client. The formulation development studies would be conducted using suitable laboratory
scale equipment. If stated in the formulation development section, drug product will be hand packaged into suitable containers for the stability study. 
 Prototype Manufacturing 
 Manufacturing batch records that specify the manufacturing procedures and acceptance criteria will be prepared by
Patheon and submitted to the Client for information. 
 Report 
 Upon completion of the manufacturing activities, a formulation development report (one formulation development report would include all formulation development activities up until and including prototype batch manufacture) will be provided
to the Client for review and approval. 
 G) Manufacturing Validation 
 Master Validation Plan 
  

							
	x	  	Applicable	  	 ̈	  	Not Applicable

 This high level document outlines the planned validation activities. The price includes protocol generation
and approval. For multiple strengths, a single master validation plan is typically generated.
 Process Validation 
  

							
	x	  	Applicable	  	 ̈	  	Not Applicable

 The process validation includes the generation and approval of the process validation protocol, execution of the
validation batches, and the generation and approval of a final process validation report. Three batches per strength are to be manufactured. For multiple strengths, separate protocols and reports will be generated. The specific
testing plan for a process validation is not known at the time of quotation, therefore the pricing is based on the following assumptions for testing and sampling of solid dose products on a per batch basis. Blender and drums: blend uniformity
(up to a total of 24 samples), 

  

 ARCA Discovery, Inc. 
 Bucindolol HCl Tablets (six strengths) - Technology Transfer 
 Page 22 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

 
physical blend testing (bulk/tapped density, sieve analysis); Cores: Beginning, middle and end (30 cores for content uniformity), ID, appearance,
dissolution, water content; Coated Tablets (one coating pan): release testing per pan, (ID, appearance, potency, content uniformity, related substances, dissolution, weight variation, water content, micro).
 For liquids and semi-solids, it is assumed that the testing consists of the following: ID, appearance, blend homogeneity, potency and related substances, viscosity,
foreign particulate testing, specific gravity and micro. These tests could be performed on the primary finished pack (eg uniformity within a filled tube). 
 Packaging Validation 
  

							
	x	  	Applicable	  	 ̈	  	Not Applicable

 The packaging validation includes the generation and approval of the packaging validation protocol, execution time
for the validation batches, and the generation and approval of a final packaging validation report. Packaging validation is a standard solid dose or semi-solid/liquid into a single SKU (stock keeping unit), and that three batches are to be
packaged per SKU. For additional strengths or SKUs, it is assumed that there will be a separate protocol and report generated. It is assumed that for analytical tests, only identification will be required during the packaging
activities. Packaging validation will analyze for fill count, fill volume, labeling, lot numbering and expiration date printing, cartoning, tube crimping, tube seal, bottle/cap seal etc. 
 Bulk Hold Time Study 
  

							
	 ̈	  	Applicable	  	x	  	Not Applicable

 The bulk hold time study includes the generation and approval of a protocol, the execution of the protocol, and
the generation and approval of a final report. It is assumed that the study will be conducted for one strength, for each of the blend (solid or liquid/semi solid), cores and coated tablets. Three time points is assumed for the study and
that the testing will consist of the following: Blend: potency and related substances; Cores: Appearance, dissolution, water content, potency and related substances Coated Tablets: ID, appearance, potency and related
substances, dissolution, weight variation, water content, micro. 
 Cleaning Validation 
  

							
	x	  	Applicable	  	 ̈	  	Not Applicable

 The cleaning validation includes the generation and approval of a protocol, execution and the generation and
approval of a final cleaning validation report. It is assumed that 3 separate trials will be required for the study, and that each trial will cover up to 16 pieces of equipment (analyzed in 4 groups of 4 pieces of equipment). 
  

 ARCA Discovery, Inc. 
 Bucindolol HCl Tablets (six strengths) - Technology Transfer 
 Page 23 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

 Part B: Budget Summary 
 Once a project has been awarded to Patheon, a detailed budget will be presented to the Client that will include a budget breakdown by milestones and Unique Identity Numbers for billing. 
 [ * ] 
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 ARCA Discovery, Inc. 
 Bucindolol HCl Tablets (six strengths) - Technology Transfer 
 Page 24 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

 PART C 
 STANDARD TERMS AND CONDITIONS 
 FOR PHARMACEUTICAL DEVELOPMENT SERVICES 
  

	1.	Services: 

  

	 	(a)	Patheon agrees to perform the pharmaceutical development services described in the Project Scope (“Services”). 

  

	 	(b)	Parties must agree on changes, deletions or additions to the Services (“Changes”). 

  

	 	(c)	Minor Changes shall be confirmed by electronic mail, facsimile or other written document. Significant Changes (such as a request by the Client to change the Project Scope) shall be
confirmed by a Change of Scope Agreement. 

  

	2.	Payment and Deposit: 

  

	 	A.	Payment 

  

	 	(a)	Client shall pay Patheon for the Services as outlined in this Contract and for any Changes which shall be invoiced separately at Patheon’s then prevailing hourly rates.

  

	 	(b)	If Client causes any delay to Patheon’s provision of Services for reason within its control (such as a delay in responding to a Patheon inquiry or a delay in the delivery of
the active pharmaceutical ingredient (“API”)), then Patheon shall be entitled to charge the Client for any additional costs incurred in the provision of the Services as a result of the delay. 

  

	 	(c)	Patheon invoices may be issued upon completion of each milestone set out in the Budget Summary and shall be due and payable within 30 days of receipt of such invoice. Client may
request that Patheon forward each invoice to the facsimile number and/or email address stipulated by the Client from time to time. Interest on past due accounts will accrue at a rate of 2% per month. 

  

	 	(d)	Prior to the commencement of any Services by Patheon pursuant to this Contract, Client shall pre-pay to Patheon the amount of the estimated billings related to such Services.
Patheon will provide estimates of the monthly billings to the Client and update such estimates as required. On or before the first day of each month during the term of this Contract, Client shall forward to Patheon payment for the estimated monthly
billings for that particular month. To the extent that such estimated monthly billings are increased by Patheon following payment thereof, Client shall promptly forward to Patheon payment for the amount of such increase. These pre-payment amounts
will be credited toward monthly invoices until the Services, as modified from time to time, are fully completed or until this Contract expires or is terminated for whatever reason. All pre-payments shall be adjusted in the final invoice under this
Contract. Patheon may, at its option, suspend, from time to time, all Services until such time as the pre-payment amounts due have been received in full by Patheon. 

  

	3.	Supply of API and Materials: 

  

	 	(a)	Client shall, at its expense, supply Patheon with sufficient quantities of the API for Patheon’s use in performing the Services. 

  

	 	(b)	The costs of all third party suppliers’ fees and the purchase of project specific items (such as raw materials, excipients, packaging, special equipment, change parts,
laboratory columns and reagents, reference standards including those under the applicable United States Pharmacopoeia, the National Formulary, the British Pharmacopoeia, the European Pharmacopoeia or the Japanese Pharmacopoeia) necessary for Patheon
to perform the Services shall be purchased by Patheon and charged to Client at Patheon’s cost plus an additional 15% as a handling charge. Notwithstanding anything to the contrary contained herein, Patheon acknowledges and agrees that it will
not charge Client an additional 15% handling charge on any purchase of tooling required for the Services performed herein. 

  

	 	(c)	If applicable, Patheon and the Client will cooperate and provide such assistance to each other as may be reasonably necessary to permit the import of the API and other materials
into the country where the Services will be performed. 

  

	4.	Termination: 

  

	 	(a)	Either party may terminate this Contract if the other party is in material breach of any provisions of this Contract and the other party fails to remedy such breach within 30 days
of the date of notice of such breach by the non-breaching party. 

  

	 	(b)	Client may terminate this Contract immediately for any business reason. 

  

	 	(c)	Any re-scheduling of any part of the Services beyond 120 days requested by Client shall, at Patheon’s option, be deemed to be a termination of the Contract.

  

	 	(d)	Upon completion or expiry of the Contract or if the Client terminates the Contract for any business reason or if Patheon terminates the Contract because of: (i) Client’s
failure to cure any default within the 30 day notice period; or (ii) Client rescheduling any part of the Services beyond the 120 days, then Client shall pay to Patheon: 

  

	 	•	 	 any fees and expenses due to Patheon for the Services rendered up to the date of completion, expiry or termination; 

  

	 	•	 	 all reasonable actual costs incurred by Patheon to complete activities associated with the completion, expiry or termination and close of the Services rendered up
to the date of completion, expiry or termination including, without limitation disposal fees that may be payable in respect of any materials and supplies owned by the Client to be disposed of by Patheon; and 

  

 Page 25 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

	 	•	 	 any reasonable additional costs incurred by Patheon in connection with the Services that are required to fulfill applicable regulatory and contractual requirements.

  

	 	(e)	Client shall arrange for the pickup from the Patheon site of all materials and supplies owned by Client within 10 business days after the earlier of the completion, termination or
expiration of this Contract. Patheon shall charge a $30.00 per square foot per month storage fee for all materials and supplies stored at the Patheon site after the tenth business day following the completion, termination or expiration of the
Contract. 

  

	5.	Intellectual Property: 

  

	 	(a)	The term “Intellectual Property” includes, without limitation, rights in patents, patent applications, formulae, trade-marks, trade-mark applications, trade-names, trade
secrets, inventions, copyright, industrial designs and know-how. 

  

	 	(b)	For the term of this Contract, Client hereby grants to Patheon, a non-exclusive, paid-up, royalty-free, non-transferable license of Client’s Intellectual Property which Patheon
must use in order to perform the Services, which license Patheon may use only for the performance of the Services hereunder. 

  

	 	(c)	All Intellectual Property generated or derived by Patheon in the course of performing the Services, to the extent it is specific to the development, manufacture, use and sale of the
Client’s Product that is the subject of the Services, shall be the exclusive property of Client. 

  

	 	(d)	All Intellectual Property generated or derived by Patheon in the course of performing the Services which are not specific to, or dependent upon, Client’s Product and which have
application to manufacturing processes or formulation development of drug products or drug delivery systems shall be the exclusive property of Patheon. Patheon hereby grants to Client, a non-exclusive, paid-up, royalty-free, transferable license of
such Intellectual Property which Client may use for the manufacture of Client’s Product. 

  

	6.	Indemnity: 

  

	 	A.	Indemnification by Client 

 Subject to Sections 6B
and 6C(c), Client shall defend, indemnify and hold Patheon, its affiliates and their respective directors, officers, employees and agents (collectively, “Patheon Indemnitees”) harmless from and against any and all third-party actions,
causes of action, costs (including reasonable legal fees), claims, damages, liabilities and expenses (collectively, “Losses”) relating to or arising from: 
  

	 	•	 	 the manufacture (except as may be contemplated by the Services) or distribution of the Client’s Product or the use of the Client’s Product by patients
either as part of or outside of the scope of any clinical trials; 

  

	 	•	 	 the performance of the Services in accordance with the terms of this Contract; 

  

	 	•	 	 any misrepresentation, negligence or willful misconduct by Client or any of its affiliates and their respective directors, officers, employees and agents
(collectively, “Client Indemnitees”); 

  

	 	•	 	 any breach by the Client of the Client’s obligations or warranties under this Contract; or 

  

	 	•	 	 any claim of infringement or alleged infringement of any third party’s intellectual property rights in respect of the Client’s Product.

 This indemnity shall not apply to the extent that such Losses are: 
  

	 	•	 	 determined to have resulted from the negligence or willful misconduct of Patheon; or 

  

	 	•	 	 for which Patheon is obligated to indemnify the Client Indemnitees pursuant to Section 6B. 

  

	 	B.	Indemnification by Patheon 

 Subject to Sections 6A
and 6C(c), Patheon shall defend, indemnify and hold the Client Indemnitees harmless from and against any and all Losses resulting from, relating to or arising from the breach by Patheon of any of its obligations or warranties under this Contract
except to the extent that such Losses are: 
  

	 	•	 	 determined to have resulted from the negligence or willful misconduct of Client; or 

  

	 	•	 	 for which Client is obligated to indemnify the Patheon Indemnitees pursuant to Section 6A. 

  

	 	C.	Limitation of Liability 

  

	 	(a)	If Patheon fails to materially perform any part of the Services in accordance with the terms of this Contract, then Client’s sole remedy, subject to subparagraph (b), shall be
to request Patheon to: 

  

	 	•	 	 repeat that part of the Service at Patheon’s costs provided that Client provides the API; or 

  

	 	•	 	 reimburse Client for the price for that part of the Service, excluding the cost of the API. 

  

	 	(b)	Under no circumstances whatsoever shall Patheon reimburse Client for the cost of the API unless the loss of API occurred through the negligence or willful misconduct of Patheon,
provided, however, that in no case shall Patheon liability for the loss of API exceed the total amount of $40,000 in any and all circumstances. Client acknowledges that the Services involve scientific experiments that require the use of judgment and
any loss of API in exercising such judgment shall not be regarded as loss due to Patheon’s negligence or willful misconduct. 

  

	 	(c)	Under no circumstances whatsoever shall either party be liable to the other in contract, tort, negligence, breach of statutory duty or otherwise for (i) any (direct or
indirect) loss of profits, of production, of anticipated savings, of business or goodwill or (ii) any other liability, damage, cost or expense of any kind incurred by the other party of an indirect or consequential nature, regardless of any
notice of the possibility of such damages. 

  

	 	D.	No Warranty 

 PATHEON MAKES NO WARRANTY OF ANY KIND,
EITHER EXPRESSED OR IMPLIED, BY FACT OR LAW, OTHER THAN THOSE EXPRESSLY SET FORTH IN THIS CONTRACT. PATHEON MAKES NO WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE OR WARRANTY OF MERCHANTABILITY IN RESPECT OF THE CLIENT’S PRODUCT. 
  

 Page 26 of 29 
 CONFIDENTIAL 

 Patheon Proposal # ARC-FYM1-0800-0406-R5 
 21-September-2006 
  

	7.	Regulatory Filings:  

  

	 	(a)	Client shall have the sole responsibility for filing of all documents with the applicable regulatory authority (such as the United States Food and Drug Administration
(“FDA”), the Health Products and Food Branch of Health Canada or the European Medicine Evaluation Agency) (the “Regulatory Authority”) and to take any other actions that may be required for the receipt of approval from the
Regulatory Authority for the commercial manufacture of the Client’s Product. 

  

	 	(b)	At least 21 days prior to filing any documents with the Regulatory Authority that incorporate data generated by Patheon, Client shall provide Patheon with a copy of the documents
incorporating such data so as to give Patheon the opportunity to verify the accuracy and regulatory validity of such documents as it relates to the Patheon-generated data. 

  

	 	(c)	If Patheon is selected as the commercial site of manufacture of the Product which is the subject of the Services under this Contract, then at least 21 days prior to filing with the
Regulatory Authority any documentation which is or is equivalent to the FDA’s Chemistry and Manufacturing Controls (“CMC”) portion of the New Drug Application or of the Abbreviated New Drug Application, as the case may be, Client
shall provide Patheon with a copy of the CMC portion as well as all supporting documents which have been relied upon to prepare the CMC portion. Such disclosure shall permit Patheon to verify that the CMC portion accurately describes the Services
that Patheon has performed and the manufacturing processes that Patheon will perform pursuant to this Contract. 

  

	8.	Shipping (if applicable): 

 Shipments (if applicable) of
Client’s Product shall be made EXW (as defined in INCOTERMS 2000) Patheon’s shipping point unless otherwise mutually agreed. Risk of loss or of damage to such Product shall transfer to the Client when the Product is loaded onto the
carrier’s vehicle by Patheon for shipment at the EXW point. The Product shall be transported in accordance with the Client’s instructions. 
  

	9.	Miscellaneous: 

  

	 	A.	Assignment 

 Neither this Contract, nor any of
either party’s rights hereunder, may be assigned or otherwise transferred by either party without the prior written consent of the other party, which consent shall not be unreasonably withheld. 
  

	 	B.	Force Majeure 

 Except for payment obligations,
neither party will be responsible for delay or failure in performance resulting from acts beyond the reasonable control and without the fault or negligence of such party, including, but not limited to, strikes or other labour disturbances, lockouts,
quarantines, communicable disease outbreaks, riots, wars, acts of terrorism, fires, floods, storms, interruption of or delay in transportation, defective equipment, lack of or inability to obtain fuel, power or components or compliance with any
order or regulation of any government entity. 
  

	 	C.	Survival 

 Any termination or expiration of this
Contract shall not affect any outstanding obligations or payments due hereunder prior to such termination or expiration, nor shall it prejudice any other remedies that the parties may have under this Contract. The Confidentiality Agreement and
sections 4, 5, 6 and 7 of the Contract shall survive the expiration or termination of this Contract. 
  

	 	D.	Independent Contractors 

 The parties are
independent contractors and this Contract shall not be construed to create between Patheon and the Client any other relationship such as, by way of example only, that of employer-employee, principal, agent, joint-venturer, co-partners or any similar
relationship. 
  

	 	E.	Confidentiality 

 The Confidentiality Agreement
entered into between the parties shall apply to all confidential information about the parties and the Services to be conducted under this Contract and such Confidentiality Agreement is deemed to be incorporated herein by reference. If the
Confidentiality Agreement expires or terminates prior to the expiration or termination of this Contract, then the terms of the Confidentiality Agreement shall nonetheless continue to govern the parties’ obligations of confidentiality for the
term of this Contract and for 5 years thereafter. 
  

	 	 F.
	 Patheon PartnerTM

 In order to participate in the
PatheonPartnerTM program, Client must submit a completed PatheonPartnerTM External User Account/Access Form to its Patheon project manager. If applicable, the PatheonPartnerTM External
User Account/Access Form signed by the Client shall apply to the Client’s use of the PatheonPartnerTM website in respect of the Services.

  

	 	G.	Other Terms 

 No terms, provisions or conditions of
any purchase order or other business form or written authorization used by Client or Patheon will have any effect on the rights, duties or obligations of the parties, or otherwise modify, this Contract, regardless of any failure of Client or Patheon
to object to such terms, provisions, or conditions unless such document specifically refers to this Contract and is signed by both parties. 
  

	 	H.	Insurance 

 Each party shall maintain during the
term of this Contract general liability and product liability insurance. Either party may request evidence of such insurance. 
  

	 	I.	Entire Agreement 

 This Contract constitutes the
complete agreement between the parties with respect to this subject matter and supersedes all other prior agreements and understandings, whether written or oral. Any modifications, amendment or supplement to this Contract must be in writing and
signed by authorized representatives of both parties. 
  

	 	J.	Facsimile 

 This Contract may be signed in
counterparts and by facsimile. 
  

	 	K.	Choice of Law 

 This Contract is governed by the
laws of the State of Delaware applicable therein, without regard to any conflicts-of-law principle that directs the application to another jurisdiction’s law. 
 [ * ] 
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule
24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 Page 27 of 29 
 CONFIDENTIAL

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}]]